Michael R Hayden
Overview
Explore the profile of Michael R Hayden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
415
Citations
19538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shefner J, Oskarsson B, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA
. 2025 Mar;
PMID: 40067755
Importance: Amyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention. Objective: To determine the effects of pridopidine, a σ1-receptor agonist, in...
2.
Goldberg Y, Navon-Perry L, Cruz-Herranz A, Chen K, Hecker-Barth G, Spiegel K, et al.
CNS Drugs
. 2025 Mar;
PMID: 40055280
Background: Huntington's disease (HD) is a rare, fatal, chronic progressive neurodegenerative disorder with a significant unmet medical need for effective treatments. Pridopidine is a novel, first-in-class, highly selective and potent...
3.
Tan A, Geva M, Goldberg Y, Schuring H, Sanson B, Rosser A, et al.
J Huntingtons Dis
. 2025 Feb;
14(1):16-29.
PMID: 39973394
Huntington's disease (HD) is a progressive neurodegenerative disorder marked by motor, cognitive, and behavioral impairments. Antidopaminergic medications (ADMs), such as VMAT2 inhibitors and antipsychotics, are commonly used to manage HD...
4.
Findlay Black H, Kay C, Dawson J, Bortnick S, Javier K, Xia Q, et al.
Genet Med Open
. 2024 Dec;
2:101882.
PMID: 39669608
Purpose: In Huntington disease (HD), synonymous variants causing loss or duplication of the interrupting CAA codon in the CAG repeat modify disease onset. These variants are undetectable during HD genetic...
5.
Monteiro-Cardoso V, Yeo X, Bae H, Mayan D, Wehbe M, Lee S, et al.
J Lipid Res
. 2024 Nov;
66(1):100712.
PMID: 39577772
Bile acids are liver-derived signaling molecules that can be found in the brain, but their role there remains largely unknown. We found increased brain chenodeoxycholic acid (CDCA) in mice with...
6.
Harding R, Xie Y, Caron N, Findlay-Black H, Lyu C, Potluri N, et al.
bioRxiv
. 2024 Oct;
PMID: 39386513
Huntington disease (HD) is a progressive and devastating neurodegenerative disease caused by expansion of a glutamine-coding CAG tract in the huntingtin () gene above a critical threshold of ~35 repeats...
7.
Caron N, Byrne L, Lemarie F, Bone J, Aly A, Ko S, et al.
Transl Neurodegener
. 2024 Oct;
13(1):50.
PMID: 39380076
Background: Therapeutic approaches aimed at lowering toxic mutant huntingtin (mHTT) levels in the brain can reverse disease phenotypes in animal models of Huntington's disease (HD) and are currently being evaluated...
8.
Sogorb-Gonzalez M, Landles C, Caron N, Stam A, Osborne G, Hayden M, et al.
Brain
. 2024 Aug;
147(12):4043-4055.
PMID: 39155061
Huntington's disease (HD) is a fatal neurodegenerative disease caused by a trinucleotide repeat expansion in exon 1 of the huntingtin gene (HTT) that results in toxic gain of function and...
9.
Dawson J, Kay C, Findlay Black H, Bortnick S, Javier K, Xia Q, et al.
Genet Med
. 2024 Aug;
26(11):101239.
PMID: 39140258
Purpose: To determine the frequency and clinical impact of loss-of-interruption (LOI) and duplication-of-interruption modifier variants of the HTT CAG and CCG repeat in a cohort of individuals with Huntington disease...
10.
Neel D, Baselga-Garriga C, Benson M, Keegan M, Chase M, DAgostino D, et al.
Muscle Nerve
. 2024 Jun;
70(2):232-239.
PMID: 38842106
Introduction/aims: Expanded access (EA) is a Food and Drug Administration-regulated pathway to provide access to investigational products (IPs) to individuals with serious diseases who are ineligible for clinical trials. The...